Logo image of PRPH

PROPHASE LABS INC (PRPH) Stock Fundamental Analysis

NASDAQ:PRPH - Nasdaq - US74345W1080 - Common Stock - Currency: USD

0.3808  +0.01 (+1.9%)

After market: 0.386 +0.01 (+1.37%)

Fundamental Rating

0

Overall PRPH gets a fundamental rating of 0 out of 10. We evaluated PRPH against 195 industry peers in the Pharmaceuticals industry. PRPH has a bad profitability rating. Also its financial health evaluation is rather negative. PRPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRPH has reported negative net income.
In the past year PRPH has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: PRPH reported negative net income in multiple years.
PRPH had negative operating cash flow in 4 of the past 5 years.
PRPH Yearly Net Income VS EBIT VS OCF VS FCFPRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

With a Return On Assets value of -106.49%, PRPH is not doing good in the industry: 75.90% of the companies in the same industry are doing better.
PRPH has a worse Return On Equity (-352.98%) than 76.41% of its industry peers.
Industry RankSector Rank
ROA -106.49%
ROE -352.98%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
PRPH Yearly ROA, ROE, ROICPRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRPH Yearly Profit, Operating, Gross MarginsPRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRPH has more shares outstanding
PRPH has a worse debt/assets ratio than last year.
PRPH Yearly Shares OutstandingPRPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
PRPH Yearly Total Debt VS Total AssetsPRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -3.65, we must say that PRPH is in the distress zone and has some risk of bankruptcy.
PRPH has a Altman-Z score (-3.65) which is in line with its industry peers.
A Debt/Equity ratio of 0.46 indicates that PRPH is not too dependend on debt financing.
The Debt to Equity ratio of PRPH (0.46) is worse than 60.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -3.65
ROIC/WACCN/A
WACC15.51%
PRPH Yearly LT Debt VS Equity VS FCFPRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

PRPH has a Current Ratio of 1.03. This is a normal value and indicates that PRPH is financially healthy and should not expect problems in meeting its short term obligations.
PRPH has a Current ratio of 1.03. This is amonst the worse of the industry: PRPH underperforms 82.05% of its industry peers.
PRPH has a Quick Ratio of 1.03. This is a bad value and indicates that PRPH is not financially healthy enough and could expect problems in meeting its short term obligations.
PRPH has a worse Quick ratio (0.98) than 75.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.98
PRPH Yearly Current Assets VS Current LiabilitesPRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PRPH have decreased strongly by -123.15% in the last year.
PRPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.65%.
PRPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.32% yearly.
EPS 1Y (TTM)-123.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-60.62%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.59%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRPH Yearly Revenue VS EstimatesPRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PRPH Yearly EPS VS EstimatesPRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRPH Price Earnings VS Forward Price EarningsPRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRPH Per share dataPRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROPHASE LABS INC

NASDAQ:PRPH (6/3/2025, 8:00:00 PM)

After market: 0.386 +0.01 (+1.37%)

0.3808

+0.01 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-20 2025-05-20/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners8.33%
Inst Owner Change112.4%
Ins Owners11.16%
Ins Owner Change0%
Market Cap15.82M
Analysts82.86
Price Target16.32 (4185.71%)
Short Float %0.6%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-262.88%
Min EPS beat(2)-549.51%
Max EPS beat(2)23.75%
EPS beat(4)1
Avg EPS beat(4)-378.91%
Min EPS beat(4)-957.84%
Max EPS beat(4)23.75%
EPS beat(8)2
Avg EPS beat(8)-202.92%
EPS beat(12)4
Avg EPS beat(12)-167.63%
EPS beat(16)6
Avg EPS beat(16)-151.74%
Revenue beat(2)0
Avg Revenue beat(2)-103.67%
Min Revenue beat(2)-164.6%
Max Revenue beat(2)-42.74%
Revenue beat(4)0
Avg Revenue beat(4)-93.18%
Min Revenue beat(4)-164.6%
Max Revenue beat(4)-42.74%
Revenue beat(8)0
Avg Revenue beat(8)-67.78%
Revenue beat(12)4
Avg Revenue beat(12)-38.3%
Revenue beat(16)7
Avg Revenue beat(16)-22.1%
PT rev (1m)0%
PT rev (3m)-13.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-225%
EPS NY rev (1m)0%
EPS NY rev (3m)-216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-89.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-84.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.34
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 20.2
EV/EBITDA N/A
EPS(TTM)-2.41
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.16
BVpS0.36
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.49%
ROE -352.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.5%
Cap/Sales 0.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 0.98
Altman-Z -3.65
F-Score1
WACC15.51%
ROIC/WACCN/A
Cap/Depr(3y)42.96%
Cap/Depr(5y)127.08%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y75.59%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-60.62%
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-82.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-730.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-280.78%
OCF growth 3YN/A
OCF growth 5YN/A